Cannasoul Analytics Overview
Cannasoul is an Israeli cannabis drug-discovery company developing therapeutics derived from natural compounds. Cannasoul's proprietary analytical platform, data-driven approach, knowhow, and clinical trial framework support active compound identification and development, from botanical extract through clinical approved formulation. Cannasoul has analyzed over 100 cannabinoids and 100 terpenes. The company's subsidiaries include MyPlant Bio, Psyga Bio, Nidra Logic, and CaVnox.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology - TipRanks.com
Synaptogenix, Inc., a biopharmaceutical company, has acquired a 25% stake in Cannasoul Analytics Ltd. for up to $4 million. The investment is aimed at supporting research and development of cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications. Cannasoul, founded by the Technion Research & Development Foundation and Professor Dedi Meiri, has developed technology in large disease markets including leukemia, epilepsy, and sleep disorders. As part of the investment agreement, Synaptogenix obtains a preemptive right to fund further research and commercialization of certain intellectual property, technology, and future products developed by Cannasoul and licensed from The Technion.
PartnersAcquisitionInvestment
growth-positive
Eybna and CannaSoul, Top Cannabis R&D Firms, Join Forces to Prove a Proprietary Terpene Formulation for Treating Viral Infections via Modulation of Cytokine Storm
CannaSoul and Eybna Technologies Ltd have announced a partnership to jointly engage in assays of CannaSouls Cytokine Storm Assay and Eybnas Novel NT-VRL formulation. The collaboration aims to optimize the anti-inflammatory and anti-viral properties of Eybnas NT-VRL terpene formulation. The NT-VRL formulation is aimed at fighting viral diseases, including COVID-19. The companies aim to develop effective treatment that is easily accessible to patients worldwide.
Partners
growth-positive
Kensana Health Enters Joint Venture With Cannasoul Analytics
PRM Inc. is rebranding as Kensana Health. The article discusses the companys focus on leveraging plant-based therapies to revolutionize wound healthcare. It also mentions the rejection of eCS Vets application to improve CBD legislation for the benefit of animal health and welfare. Additionally, it highlights the opening of a public consultation on a proposed amendment to the Poisons Standard.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $4M |
| Last funding | $4M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | cannasoul.co.il/ |
Locations
Tarshish St 5, Caesarea, Israel
Photos & Videos
2 item(s)
